Barry Simon Sells 10,000 Shares of ImmunityBio (NASDAQ:IBRX) Stock

ImmunityBio, Inc. (NASDAQ:IBRX) Director Barry Simon sold 10,000 shares of the stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $9.25, for a total transaction of $92,500.00. Following the sale, the director directly owned 3,081,604 shares in the company, valued at $28,504,837. This trade represents a 0.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

ImmunityBio Stock Down 17.4%

NASDAQ:IBRX opened at $9.54 on Thursday. The stock has a market cap of $9.81 billion, a price-to-earnings ratio of -25.11 and a beta of 0.16. The company’s 50 day moving average price is $4.97 and its 200-day moving average price is $3.28. ImmunityBio, Inc. has a 52 week low of $1.83 and a 52 week high of $12.43.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $38.29 million during the quarter. As a group, sell-side analysts anticipate that ImmunityBio, Inc. will post -0.92 earnings per share for the current year.

Key ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Huge ANKTIVA-driven sales beat expectations — company reported roughly 600–700% year‑over‑year revenue growth as ANKTIVA adoption ramps, which underpins the recent sharp share advance. Read More.
• Positive Sentiment: Q4 beat on EPS and revenue — ImmunityBio posted a smaller-than-expected loss (reported -$0.06 vs. consensus -$0.08) and stronger revenue (~$38.3M), giving investors proof that commercial revenue is scaling. Read More.
• Positive Sentiment: Regulatory/commercial expansion for ANKTIVA — approvals and new global partnerships broaden the addressable market and support multi‑market rollout plans. Read More.
• Neutral Sentiment: Analyst activity is mixed — some boutiques reiterated/raised long‑term targets (e.g., D. Boral Capital buy), while HC Wainwright trimmed several near‑term EPS forecasts but kept a buy stance and higher out‑years, leaving guidance interpretation mixed for traders. Read More.
• Neutral Sentiment: Founder and management visibility — presentations at cancer summits increase profile and credibility but are unlikely to change near‑term cash flow. Read More.
• Negative Sentiment: Profit‑taking after rapid run-up — the stock pulled back sharply (reported intraday ~17% drop) as traders locked gains following the surge toward 52‑week highs. Read More.
• Negative Sentiment: Insider sales — director Barry J. Simon disclosed multiple share sales (including a large block on Feb. 23), which can amplify short‑term selling pressure and concern among some investors. Read More.
• Negative Sentiment: Company remains unprofitable — despite revenue momentum, consensus still expects negative EPS for the current year, leaving valuation and execution risk elevated for longer‑term holders. Read More.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on IBRX. HC Wainwright upped their price objective on ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. Jefferies Financial Group increased their price objective on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Piper Sandler boosted their target price on shares of ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a report on Monday. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, ImmunityBio currently has an average rating of “Moderate Buy” and an average price target of $12.60.

Institutional Investors Weigh In On ImmunityBio

A number of institutional investors have recently added to or reduced their stakes in the stock. Slow Capital Inc. bought a new position in shares of ImmunityBio during the third quarter worth $25,000. Envision Financial Planning LLC bought a new position in shares of ImmunityBio during the 2nd quarter valued at about $28,000. Summit X LLC purchased a new position in shares of ImmunityBio during the second quarter valued at about $28,000. Diversify Advisory Services LLC purchased a new position in shares of ImmunityBio during the second quarter valued at about $27,000. Finally, Truist Financial Corp bought a new stake in shares of ImmunityBio in the third quarter worth about $27,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.